Skip to main content
. 2013 Jul 12;6(3):667–672. doi: 10.3892/ol.2013.1459

Figure 4.

Figure 4

Quantitative analysis of intratumoral (A) 3H-FLT distribution and (B) Ki-67 labeling index on days three and seven following treatment with vehicle or sorafenib. 3H-FLT, [methyl-3H(N)]-3′-fluoro-3-′deoxythymidine; ID, injected dose; Control, control group; Sorafenib, sorafenib-treated group. *P<0.01.